Beluga Health Alternatives for Telehealth Brands

What problem should a Beluga Health alternative solve?

Beluga’s documented architecture supports direct API, hosted intake and platform-partner routes. That means the product you experience may combine Beluga with a separate commerce platform. Before searching for a substitute, identify which layer is responsible for the issue you want to solve.

If the concern is a clinical pathway, evaluate the proposed clinician arrangement, state coverage and escalation process. If it is checkout, subscriptions or support visibility, a clinical-backend change alone may leave the problem in place. The TEHR versus Beluga Health comparison explains these scope boundaries.

An existing brand should inventory its merchant account, pharmacy contracts, patient portal and record systems. Decide which relationships should remain. A suitable alternative can either respect that architecture or replace more of it with a clearly scoped operation, but the vendor must show how the chosen approach works for continuing patients as well as new ones.

Which operating models belong on the shortlist?

This shortlist groups different operating models. The order is editorial, with TEHR first, and does not represent independent testing or numerical scores. Vendor statements are presented as of October 22, 2026; a missing public detail means it needs confirmation, not that the capability is absent.

When is TEHR the right alternative to evaluate?

TEHR combines white-label technology and administrative infrastructure with an independent licensed clinical network reaching all 50 states, subject to program, state and patient eligibility. It supports clinician e-prescribing, pharmacy coordination, AI-assisted intake, payments and subscriptions. Clinical decisions remain with independent licensed providers. Its commercial model is a flat platform subscription plus flat transaction fee and 0% revenue share; contact TEHR for a scoped quote. See the platform and pricing scope.

TEHR is worth evaluating when the objective is to bring brand technology and administrative workflows into a more coordinated operating relationship. Ask what TEHR would replace and what it would retain from a Beluga-connected stack. The answer should cover commerce, recurring billing, support and the independent clinical relationship rather than presenting a new clinical integration as a complete transformation.

Trade-off: Confirm the actual clinical, pharmacy, support and integration scope before treating a platform proposal as an all-inclusive service. Patients see the brand, while required notices still identify the real care entities. Selected peptide programs are pending and are not open for prescribing or fulfillment.

When should you consider MD Integrations?

Strength: MD Integrations describes a physician-only network and both API and ready-made patient workflows. Its FAQ covers pharmacy fulfillment and tailored pricing, and explicitly states that it does not prescribe controlled substances. That limitation matters when evaluating a proposed hormone program. Official platform and physician network; FAQ.

Consider MD Integrations when physician-only clinical staffing is a specific procurement preference and the proposed programs fit its stated prescribing scope. Its controlled-substance exclusion is a material filter, not a footnote. Review your actual catalog before spending engineering time on an integration that may not serve the intended treatment mix.

Trade-off: Do not infer testosterone prescribing from a broad hormone or men’s-health category. Confirm program eligibility and the exact commercial scope before integrating. The reviewed sources do not establish a standard patient-migration service or a universal numerical rate card.

When should you consider SteadyMD?

Strength: SteadyMD describes a 50-state clinical workforce and clinical operations. Its API materials distinguish limited integration, where clinical work happens in the partner’s EMR, from complete integration using SteadyMD’s EMR. Patient records, intake and diagnostic information can be included in the workflow. Official digital health companies; Telehealth APIs.

Consider SteadyMD when you want clinical workforce flexibility while preserving an existing patient experience or EMR. Compare its limited and complete integration routes with the architecture you already use. Ask how clinical notes, diagnostic results and messages remain accessible to the people responsible for the next stage of care.

Trade-off: Do not mistake clinical staffing and integration for a confirmed turnkey commerce package. Request the proposed pharmacy, payment, subscription and administrative scope, plus actual pricing. The reviewed sources do not establish a standard bulk-migration service or deadline.

When should you consider Wheel?

Strength: Wheel’s Horizon offering combines a configurable platform, clinician network and clinical operations. Its launch page describes an EMR, branded patient experience and modular programs; connected services include prescription fulfillment, pharmacy delivery and laboratory connections. Official launch virtual care; Connected services.

Consider Wheel when the goal extends beyond substituting a clinical API to configuring a broader care program. Ask how its patient experience and connected services map to your distribution model. Compare the full proposed package with the systems and staff currently surrounding Beluga so neither side is credited with unpriced work.

Trade-off: The reviewed public pages do not establish universal numeric pricing or revenue-share terms. Ask how the exact channel, program, patient experience and service connections are packaged. A connection to a service does not necessarily include the cost of using that service.

When should you consider Lithos Health?

Strength: Lithos describes a white-label medical practice delivered through an API while customers build their own product. Its pricing page publishes per-completed-visit bands, and its migration page describes staged transitions with parallel testing and clinical continuity work. Official practice infrastructure; Pricing.

Consider Lithos when your team wants to keep building the customer product and needs a clinical-practice API with public usage pricing. Its staged migration description is useful for planning questions. Confirm how your program, modality and source records affect the quote instead of applying the lowest published visit band to all volume.

Trade-off: The brand must account for building and operating the customer-facing product. Compare the appropriate modality and graduated volume bands, not only the lowest advertised visit rate. Public migration guidance is useful, but your source records and program still determine the plan. Migration.

When should you consider OpenLoop?

Strength: OpenLoop’s Launchpad describes a no-code website, branded portal, intake, clinicians and operating workflows. The current product is broader than a clinician network; its official page also describes integration into existing customer systems. Official launchpad and platform.

Consider OpenLoop when you want to evaluate a fuller platform replacement alongside a direct backend substitution. Launchpad’s documented breadth changes the comparison: the question becomes which current systems would be retired, not just how a visit is routed. Make the business case include implementation effort and any remaining internal operations.

Trade-off: The reviewed page does not establish a universal numeric rate card or revenue-share policy. Request itemized terms and identify the work your team retains. Treat its fastest launch statement as a vendor estimate with readiness conditions, not a migration guarantee.

When should you consider Telegra?

Strength: Telegra describes intake, commerce, pharmacy routing, a branded portal/app and APIs. Its public migration documentation covers CSV imports for patients, products, coupons, orders and subscriptions, with dry-run validation before production import. This is documented import capability, not proof of every outbound export option. Official platform overview; CSV migration.

Consider Telegra when commerce and patient-facing consistency are major reasons for reviewing the current stack. An integrated portal and documented imports may help structure the project, but verify actual data coverage and plan-specific features. Separate the new patient launch from the transition of patients with active treatment or recurring orders.

Trade-off: Request recurring costs separately from published onboarding fees and confirm plan-specific app and pharmacy options. Its conditions page marks peptides Coming Soon; that is not a currently available prescribing or fulfillment program. Conditions and program status.

When should you consider Cuvo Health?

Strength: Cuvo’s pricing page publishes platform plans and a completed-consult charge, explicitly states no revenue share or added platform transaction fee, and describes patient/data migration without an additional migration charge. It also distinguishes full-platform plans from its existing-stack Prescribe option. Official pricing.

Consider Cuvo when you want explicit public plan structure and a stated migration offer in the shortlist. Its no-revenue-share claim does not distinguish it from Beluga by itself. Compare the complete fee events and operational responsibilities, especially the cost of clinical activity and the work included in migration assistance.

Trade-off: Include setup, recurring and clinical charges in the comparison; standard payment-processing and other delivery costs still matter. A clinical connection to an existing stack has different dependencies from building a full brand. Confirm what its migration offer covers for your actual records.

How should you narrow the shortlist?

Split the evaluation into clinical suitability and operating fit. A candidate that cannot support the intended program should not advance merely because its software is attractive. Once the clinical configuration is established, compare intake, patient communication, subscriptions, pharmacy routing and administrative support.

Use a responsibility map to expose gaps between companies. Who owns a patient question that begins as a shipping issue but becomes a clinical concern? Who updates the commercial system after the clinician changes the treatment plan? Who resolves an integration event that did not arrive? Ask finalists to demonstrate these handoffs.

The TEHR pricing discussion should be matched to a complete alternative proposal. Retained commerce software and staff remain part of the cost even when the new clinical quote looks simple. A modular approach may still be the better choice if those retained capabilities are valuable and well managed.

How should existing patients move to the chosen platform?

Beluga publicly describes incoming migrations on its switching page. That does not establish the export terms for your own account or for a separate platform connected to it. Locate each source of records and commercial data, then obtain authorized samples before estimating the transition.

Use the Beluga migration guide and migration checklist to coordinate patient identity, clinical history, consents, lab results, pharmacy relationships and billing. Test the next action for a continuing patient. A correct import is insufficient if the new team cannot safely determine what should happen next.

What should the final proposal make explicit?

Ask for the service boundaries, itemized charges, implementation dependencies and operational acceptance criteria in writing. Review the white-label telehealth guide if the proposals use the same label for different scopes, and use the resource library to prepare program and migration questions. A good shortlist should become a small set of comparable proposals. It should not end as a ranking that hides unanswered questions about who supplies care, who performs administrative work and what the brand will actually pay.

For a wider category view, compare the white-label telehealth platform shortlist and the turnkey telehealth platform shortlist. Use the first to examine brand and architecture choices, and the second to assess which implementation and operating tasks a proposed package actually supplies.

What else should you know?